ZyVersa CEO Stephen Glover said, “ZyVersa is developing Inflammasome ASC Inhibitor IC 100 for treatment of chronic inflammatory diseases, with ...

Ascentage Pharma (AAPG) announced that two of its proprietary novel drugs have been included in the 2025 Chinese Society of Clinical Oncology, ...